ADAM17 and central nervous system cancer: Furthermore, ADAM17 knockdown downregulated mesenchymal markers expression and elicited E-cadherin expression (Fig. 2f, Supplementary Fig. S3e–f), which is consistent with the results of FoxM1 knockdown in glioma cells.